Saegusa Tatsuya, Koizumi Tomonobu, Komatsu Yoshimichi, Yasuo Masanori, Urushihata Kazuhisa, Fujimoto Keisaku, Kubo Keishi
First Dept. of Internal Medicine, Shinshu University School of Medicine.
Gan To Kagaku Ryoho. 2006 Dec;33(13):2053-6.
A 65-year-old woman with relapsed non small cell lung cancer, who had no prior chemotherapy, was admitted to our hospital. She was initially treated with paroxetine, a selective serotonin-reuptake inhibitor antidepressant, and received cisplatin-based chemotherapy three days after the initiation of the paroxetine. She developed hyponatremia on day 5 after the start of chemotherapy. Based on the laboratory examinations, the syndrome of inappropriate secretion of antiduretic hormone was suggested. Her plasma sodium concentration returned to normal after paroxetine withdrawal and appropriate fluid restriction. Cisplatin-based chemotherapies were subsequently continued without paroxetine and there were no further episodes of electrolyte disturbance. Paroxetine has been used widely for treatment of depressed patients with malignancies. However, careful monitoring of plasma sodium is needed following cisplatin-based chemotherapy in patients taking paroxetine.
一名65岁复发的非小细胞肺癌女性患者入院，此前未接受过化疗。她最初接受选择性5-羟色胺再摄取抑制剂抗抑郁药物帕罗西汀治疗，并在开始使用帕罗西汀三天后接受含顺铂的化疗。化疗开始后第5天她出现低钠血症。基于实验室检查，考虑为抗利尿激素分泌不当综合征。停用帕罗西汀并适当限制液体摄入后，她的血浆钠浓度恢复正常。随后在未使用帕罗西汀的情况下继续进行含顺铂的化疗，未再出现电解质紊乱情况。帕罗西汀已广泛用于治疗患有恶性肿瘤的抑郁症患者。然而，在接受含顺铂化疗的服用帕罗西汀的患者中，需要密切监测血浆钠水平。
